# UK Medical Cannabis Registry: Two-Year Clinical Outcomes in Depression > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/uk-medical-cannabis-registry-depression-outcomes/ > **Published:** 2026-03-26T00:07:43-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:08:34-04:00 > **Clinical Summary:** Explore UK Medical Cannabis Registry depression outcomes showing real-world clinical data on cannabis-based medicinal products over two years. --- CED Clinical Relevance  #90High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic DepressionMental HealthRegistry StudyAnxietyCbmp Journal Journal of affective disorders Study Type Observational Study Population Human participants Why This Matters This represents the largest longitudinal dataset examining cannabis-based medicinal products for depression, addressing a significant evidence gap in mood disorders. Registry data provides real-world clinical outcomes that complement controlled trials. Clinical Summary This observational study tracked 698 depression patients from the UK [Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) Registry over 24 months, measuring PHQ-9, GAD-7, sleep quality, and [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) scores. The registry format captured routine clinical practice with CBMPs prescribed by specialist physicians. While the abstract indicates improvements, the full methodology and control for confounding variables typical in registry studies would need evaluation. Notable limitations include lack of randomization and potential selection bias inherent to specialty cannabis clinics. Dr. Caplan’s Take “Registry data fills important gaps but cannot establish causation – these patients were receiving specialized care beyond just cannabis, and we’re seeing those who stayed engaged with treatment. This adds to the evidence base but doesn’t fundamentally change my approach to depression management.” Clinical Perspective 🧠 Clinicians should view this as supportive observational data rather than definitive evidence for CBMPs in depression. Patients interested in cannabis for mood disorders still require comprehensive psychiatric evaluation and evidence-based primary treatments. This study supports the safety profile but emphasizes need for continued monitoring. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20UK%20Medical%20Cannabis%20Registry%3A%20A%20two-year%20case%20series%20of%20clinical%20outcomes%20in%20dep...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41506388/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41506388/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20UK%20Medical%20Cannabis%20Registry%3A%20A%20two-year%20case%20series%20of%20clinical%20outcomes%20in%20dep...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41506388/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41506388/](https://pubmed.ncbi.nlm.nih.gov/41506388/) Table of Contents - [FAQ](#FAQ)[How effective are cannabis-based medicinal products for treating depression?](#How_effective_are_cannabis-based_medicinal_products_for_treating_depression) - [What types of patients were included in this depression study?](#What_types_of_patients_were_included_in_this_depression_study) - [How long does it take to see improvement in depression symptoms with CBMPs?](#How_long_does_it_take_to_see_improvement_in_depression_symptoms_with_CBMPs) - [What side effects or adverse events were reported with CBMP treatment for depression?](#What_side_effects_or_adverse_events_were_reported_with_CBMP_treatment_for_depression) - [Do CBMPs help with anxiety and sleep problems commonly associated with depression?](#Do_CBMPs_help_with_anxiety_and_sleep_problems_commonly_associated_with_depression) - [Related](#Related) ## FAQ #### How effective are cannabis-based medicinal products for treating depression? This UK registry study of 698 patients showed statistically significant improvements in depression scores (PHQ-9), anxiety (GAD-7), sleep quality, and overall [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) over 24 months of CBMP treatment. The improvements were sustained across multiple time points, suggesting CBMPs may provide meaningful clinical benefits for patients with depression. #### What types of patients were included in this depression study? The study analyzed 698 patients (2.02% of the total registry) who were prescribed CBMPs specifically for depression from the UK [Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) Registry. These were real-world patients being treated in clinical practice, providing insights into how CBMPs perform outside of controlled trial settings. #### How long does it take to see improvement in depression symptoms with CBMPs? The study measured outcomes at 1, 3, 6, 12, 18, and 24 months, with statistically significant improvements observed across multiple time points. This suggests that benefits may be sustained over long-term treatment periods, though the study design doesn’t specify the earliest time point of clinically meaningful improvement. #### What side effects or adverse events were reported with CBMP treatment for depression? While the study recorded adverse events (AEs) as part of their methodology, the specific incidence and types of adverse events are not detailed in the available summary. This represents an important limitation in assessing the risk-benefit profile of CBMPs for depression treatment. #### Do CBMPs help with anxiety and sleep problems commonly associated with depression? Yes, the study found significant improvements in both anxiety symptoms (measured by GAD-7) and sleep quality (Single-Item Sleep Quality Scale) alongside depression improvements. This suggests CBMPs may address multiple interconnected symptoms commonly seen in patients with depression, potentially offering comprehensive symptom management. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “UK Medical Cannabis Registry: A two-year case series of clinical outcomes in depression.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41506388/”, “about”: “journal affective disorders observational study uk”, “isPartOf”: “Journal of affective disorders”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Clinical Implications of Real-World Evidence from the CARE Study [Response to Letter]](https://cedclinic.com/clinical-implications-real-world-evidence-cannabis-care/) Explore insights on real-world evidence from the CARE study, highlighting clinical implications relevant to [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). [Read More](https://cedclinic.com/clinical-implications-real-world-evidence-cannabis-care/) [Cannabinoid Clinical Trials for Mental Health Disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-treatment-review/) Review current [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) investigating cannabinoids for [mental health disorders](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), providing context for depression treatment research. [Explore Trials](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-treatment-review/) [UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Migraine – PubMed](https://cedclinic.com/uk-medical-cannabis-registry-migraine-outcomes-analysis/) Discover clinical outcomes from the UK Medical Cannabis Registry focusing on migraine, complementing depression registry findings. [Learn More](https://cedclinic.com/uk-medical-cannabis-registry-migraine-outcomes-analysis/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).